BioDelivery Sciences Reports Second Quarter 2021 Results

Total Company Net Revenue of $41.4 Million Driven by BELBUCA® All-Time High TRx Market Share

Strong Profitability with GAAP Net Income of $9.1 Million, or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million, or $0.12 per Share, Drives Operating Cash Generation of $9.2 Million

Announces Agreement to Acquire ELYXYB TM for the Acute Treatment of Migraine

Conference Call and Webcast Scheduled for 8:30 AM EDT Today

RALEIGH, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June 30, 2021, including the following operational and performance highlights.

“BELBUCA continued its strong double-digit revenue growth trajectory in spite of a slower-than-expected rebound in the pain market, however, we are starting to see gradual signs of market normalization,” stated Jeff Bailey, CEO of BDSI. “I am proud of the team and our ability to effectively manage the overall business, delivering an attractive 32% EBITDA margin in the quarter.”

“We are also very pleased to be adding ELYXYB to our portfolio of valuable and differentiated products, as the only ready-to-use oral solution approved for acute migraine with or without aura in adults,” Bailey added. “This differentiated drug represents a highly attractive opportunity to diversify our product portfolio, deepening our presence in neurology, a logical adjacency to our chronic pain franchise. We see this acquisition as establishing a great growth platform in neurology.”

Key Business Highlights

  • Total Company net revenue for the second quarter increased by 13% versus the prior year period to $41.4 million. This growth was driven by all-time high BELBUCA net sales of $36.5 million, which increased 13% year over year, and Symproic® net sales of $4.0 million, which increased 18% year over year.
  • BELBUCA achieved an all-time high quarterly market share of 4.7% as well as an all- time high in unique BELBUCA prescribers of 8,345 which is an increase of 11% year over year. Total BELBUCA prescriptions were approximately 119,000 during the second quarter, representing year-over-year prescription volume growth of 11%.
  • Total Symproic prescriptions were approximately 18,000 in the second quarter, up 3% versus the prior year period.
  • Strong gross margin of 89.7%, coupled with prudent management and prioritization of operating expenses, contributed to continued strong profitability, with $9.1 million of GAAP Net Income, an attractive 32% EBITDA margin, and non-GAAP Net Income of $12.5 million or $0.12 cents per share in the second quarter of 2021. Year-to-date through June 30, 2021, non-GAAP Net Income is $21.0 million or $0.20 cents per share. Both GAAP and non-GAAP net income were impacted by higher litigation spend year to date through June 30, 2021.
  • On August 3, 2021, the Company entered into an agreement to acquire the U.S. and Canadian rights to ELYXYB (celecoxib oral solution), from Dr. Reddy’s Laboratories. ELYXYB is the only ready-to-use oral solution approved by the FDA for the acute treatment of migraine, with or without aura, in adults. When launched in the US, ELYXYB will participate in a substantial and growing market, and is expected to drive the Company’s revenue growth and shareholder value while leveraging much of its existing infrastructure.
  • The Company repurchased 1.6 million shares in the quarter under its existing share buyback program, at an average price of $3.51 per share, bringing the total shares purchased to date under the program to 3.3 million shares, at an average price of $3.70.

Second Quarter 2021 Financial Results

Total Company Net Revenue for the second quarter of 2021 was $41.4 million, an increase of 13% compared to $36.6 million in the second quarter of 2020. Total product net revenue, including sales of BELBUCA and Symproic, grew 11% year over year.

BELBUCA Net Sales for the second quarter of 2021 were an all-time high of $36.5 million, an increase of 13% compared to $32.3 million in the second quarter of 2020.  

Symproic Net Sales for the second quarter were $4.0 million, an increase of 18% compared to $3.4 million in the second quarter of 2020.

Total Operating Expenses for the second quarter of 2021 were $25.8 million, compared to $28.2 million in the second quarter of 2020.

GAAP Net Income for the second quarter of 2021 was $9.1 million, or $0.09 per share, compared to GAAP net income of $1.2 million, or $0.01 per share, in the second quarter of 2020.

EBITDA for the second quarter of 2021 was $13.1 million, or 32% of net sales, compared to $5.1 million or 14% of net sales, in the second quarter of 2020.

Non-GAAP Net Income for the second quarter of 2021 was $12.5 million, or $0.12 cents per share, and reflects GAAP net income excluding stock-based compensation and non-cash amortization of intangible assets, as compared to non-GAAP net income of $9.6 million, or $0.10 cents per share, in the second quarter of 2020, excluding the same items as well as the one-time costs associated with the CEO transition in that period.

Cash Position: As of June 30, 2021, cash and cash equivalents were approximately $119.9 million, compared to $111.6 million as of December 31, 2020. The total cash flow generation year to date of $8.3 million includes continued strong operating cash generation of $20.3 million, partially offset by $11.9 million used to repurchase shares.

Financial Guidance

The Company reiterates its 2021 financial guidance, with full year 2021 total Company net sales of $170 - $180 million, including full year 2021 BELBUCA net sales of $155 - $165 million. However, due to a slower than anticipated rebound in the chronic pain selling environment associated with the COVID-19 pandemic, the Company expects BELBUCA net sales to be at the lower end of its prior guidance range. Total operating expenses are expected to be in the range of $115 - $120 million for the ongoing business, as the Company continues to invest to support the growth of its existing brands. Additionally, EBITDA remains on track to be in the $40 - $50 million range 2021 for the ongoing business. The Company continues to expect to deliver positive operating cash flow in 2021. The Company will share any updates to its guidance as a result of the ELYXYB acquisition at a future date.

“We continue to invest behind our growing brands and infrastructure to drive future growth. The persistent efforts of our commercial team permit us to continue growing our market share for BELBUCA within the long-acting opioid market. Our focus remains on helping patients with unmet needs and driving long-term shareholder value through our pain and now neurology franchises,” stated Jeff Bailey.  

Please see Important Safety Information about ELYXYB below.

Conference Call & Webcast Details

BioDelivery Sciences will host a conference call and webcast today, August 4, 2021, at 8:30 a.m. ET to present second quarter 2021 results and to provide a business update.  Dial-in details are as follows:

Date:Wednesday, August 4, 2021
Time:8:30 AM Eastern Time
Conference ID:13720500


BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.


This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of BDSI’s management and are subject to significant risks and uncertainties, including those detailed in BDSI’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the expectations for total company net sales, BELBUCA net sales, operating expenses, EBITDA and operating cash flows in 2021, the acquisition and launch of ELYXYB and growth in neurology) may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI’s control) including the risk that the current coronavirus pandemic impacts on our supply chain, commercial partners, patients and their physicians and the healthcare facilities in which they work, and our personnel are greater than we anticipate, as well as those set forth in our 2020 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP, including non-GAAP net income and EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Non-GAAP net income adjusts for one-time and non-cash charges by excluding the following from GAAP net income: stock-based compensation expense and non-cash amortization of intangible assets, as well as one-time costs associated with the CEO transition in the second quarter of 2020 and the non-recurring impact of the discontinuation of BUNAVAIL.

EBITDA excludes net interest, including both interest expenses and interest income, provision for (benefit from) income taxes, depreciation, and amortization.

The Company's management and board of directors utilize these non-GAAP financial measures to evaluate the Company's performance. The Company provides these non-GAAP measures of the Company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income and EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income and EBITDA should not be considered measures of our liquidity.

A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.


ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.



Cardiovascular Thrombotic Events
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1)].
  • ELYXYB is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].
Gastrointestinal Bleeding, Ulceration, and Perforation
  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious (GI) events [see Warnings and Precautions (5.2)].

ELYXYB is contraindicated in patients with:

  • Known hypersensitivity to celecoxib, any components of the drug product, or sulfonamides (4)
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4)
  • In the setting of CABG surgery (4)

To minimize the potential risk for an adverse cardiovascular (CV) event in NSAID-treated patients, use ELYXYB for the fewest number of days per month as needed, based on individual treatment goals. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

Avoid the use of ELYXYB in patients with a recent myocardial infarction (MI) unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ELYXYB is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

NSAIDs, including ELYXYB, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with celecoxib. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

Avoid the use of ELYXYB in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ELYXYB is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including ELYXYB.

Long-term administration of NSAIDs, including celecoxib, the active ingredient in ELYXYB, has resulted in renal papillary necrosis and other renal injury.

No information is available from controlled clinical studies regarding the use of celecoxib in patients with severe renal impairment. The renal effects of celecoxib may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month), including ELYXYB, may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.

NSAIDs, including ELYXYB, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.

Most common adverse reaction (at least 3% and greater than placebo) is dysgeusia.

These are not all the side effects associated with ELYXYB.

Please see Patient Information, Instructions For Use, Medication Guide and Full Prescribing Information for ELYXYB


© 2021 BioDelivery Sciences International, Inc.  All rights reserved.


Bob Yedid
LifeSci Advisors

 June 30,
 December 31,
Current assets:   
Cash and cash equivalents$119,853  $111,584 
Accounts receivable, net52,872  48,150 
Inventory, net18,659  17,443 
Prepaid expenses and other current assets4,680  5,208 
Total current assets196,064  182,385 
Property and equipment, net1,640  1,418 
Goodwill2,715  2,715 
License and distribution rights, net49,908  53,376 
Total assets$250,327  $239,894 
Current liabilities:   
Accounts payable and accrued liabilities$57,752  $52,995 
Notes payable, current6,154   
Total current liabilities63,906  52,995 
Notes payable, less current maturities72,472  78,452 
Other long-term liabilities31  213 
Total liabilities136,409  131,660 
Commitments and contingencies   
Stockholders’ equity:   
Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible
Preferred Stock, $0.001 par value, 443 shares outstanding at June 30, 2021 and
December 31, 2020, respectively.
Common Stock, $0.001 par value; 235,000,000 shares authorized at June 30, 2021
and December 31, 2020, respectively; 101,794,730 and 101,417,441 shares issued;
98,529,046 and 101,354,447 shares outstanding at June 30, 2021 and December 31,
2020, respectively.
104  104 
Additional paid-in capital452,550  449,264 
Treasury stock, at cost, 3,265,684 and 62,994 shares, as of June 30, 2021 and
December 31, 2020, respectively.
(12,155) (252)
Accumulated deficit(326,581) (340,882)
Total stockholders’ equity113,918  108,234 
Total liabilities and stockholders’ equity$250,327  $239,894 

 Three months ended June 30, Six months ended June 30,
 2021 2020 2021 2020
Product sales$40,523  $36,445  $81,326  $74,161 
Product royalty revenues916  137  1,132  700 
       Total revenues:41,439  36,582  82,458  74,861 
Cost of sales4,284  5,435  10,105  10,995 
Selling, general and administrative25,779  28,211  53,540  54,948 
       Total expenses:25,779  28,211  53,540  54,948 
Income from operations11,376   2,936  18,813  8,918 
Interest expense, net(1,999) (1,693) (3,977) (2,987)
Other (expense)/income, net(1) 8  (1) 8 
Income before income taxes$9,376  $1,251  $14,835  $5,939 
Income tax (provision)/recovery(312) (86) (534) 192 
Net income attributable to common
$9,064  $1,165  $14,301  $6,131 
Weighted average common stock shares
98,793,242  100,136,893  99,884,680  98,541,877 
Basic earnings per share$0.09  $0.01  $0.14  $0.06 
Weighted average common stock shares
102,508,512  108,111,201  104,009,410  107,062,161 
Diluted earnings per share$0.09  $0.01  $0.14  $0.06 

 Six months ended June 30,
 2021 2020
Operating activities:   
Net income$14,301  $6,131 
Adjustments to reconcile net income to net cash flows from operating
       Depreciation and amortization54  446 
       Accretion of debt discount and loan costs174  142 
       Amortization of intangible assets3,469  3,515 
       Provision for inventory obsolescence699  72 
       Stock-based compensation expense3,187  6,306 
       Net change in operating lease assets and liabilities(19)  
Changes in assets and liabilities:   
       Accounts receivable(4,722) (9,336)
       Inventories(1,915) (6,534)
       Prepaid expenses and other assets368  1,670 
       Accounts payable and accrued liabilities4,731  2,617 
       Taxes payable  (40)
Net cash flows provided by operating activities20,327  4,989 
Investing activities:   
       Acquisitions of equipment(415)  
Net cash flows used in investing activities(415)  
Financing activities:   
Proceeds from notes payable  20,000 
Proceeds from exercise of stock options260  2,569 
Payment on share repurchase(11,903)  
Payment on deferred financing fees  (437)
Net cash flows (used in)/provided by financing activities(11,643) 22,132 
Net change in cash and cash equivalents8,269  27,121 
Cash and cash equivalents at beginning of period111,584  63,888 
Cash and cash equivalents at end of period$119,853  $91,009 

 Three Months Ended
June 30,
 Six Months Ended
June 30,
Reconciliation of GAAP net income to EBITDA (non-GAAP)  2021 2020   2021 2020
GAAP net income$9,064 $1,165  $14,301 $6,131 
Add back/(subtract):     
Income tax recovery/(provision) 312  86   534  (192)
Net interest expense 1,999  1,685   3,977  2,979 
Depreciation and amortization 1,769  2,159   3,523  3,960 
EBITDA$13,144 $5,095  $22,335 $12,878 
Reconciliation of GAAP net income to Non-GAAP net income     
GAAP net income$9,064
Non-GAAP adjustments:     
Stock-based compensation expense 1,697  1,364   3,187  2,884 
Amortization of intangible assets 1,735  1,734   3,469  3,515 
Non-recurring financial impact of CEO transition   5,078     5,078 
Non-recurring financial impact of BUNAVAIL discontinuation   295     295 
Non-GAAP net income$12,496 $9,636  $20,957 $17,903